Infectious Disease Fellowship Research
and Scholarly Activities

2022


Donkin, J., Choi P., Holsworth, A., Hartog, N., Simeunovic, G. “No one is safe: Histoplasmosis and secondary HLH in two immunocompetent patients”. Research Day. Grand Rapids, MI. April 2022


Polega J., Simeunovic G. “Clostridium baratii cellulitis and tenosynovitis following cat bite”. Research day. Grand Rapids, Mi. April 2022


2021

Simeunovic, G. “A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults”. Regeneron. Role: Site PI. November 2021- December 2021


2020


Clark L, Beuschel T, Buss P, Jameson A, Dumkow L. “Comparison of Procalcitonin testing to a targeted audit-and-feedback strategy on prescribed durations of therapy for community-acquired pneumonia.” Diagnostic Microbiology & Infectious Disease. 4 September 2020, 115202


Simeunovic, G, “1OT2HL156812 NIH. Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO).” Role: Site Co-investigator. September 2020 – May 2021

Simeunovic, G. “A Phase 2/3 Open-label, Controlled Study to Evaluate the Safety, Tolerability, Efficacy and PK of Remdesivir in Participants from Birth to <18 years of age with COVID-19 Compared to Standard of Care Treatment or Other Experimental Treatments”. Gilead Sciences, Inc. Role: Site Co-investigator. September 2020 – present


Simeunovic, G “Remdesivir Use for COVID-19 treatment under EUA by FDA”. PI. May 2020 – October 2020


**2019**


Moorthy V, Veerasamy M, de Sanctis J. “Long Term Mechanical Circulatory Support Device and Disseminated Histoplasmosis – A Case Series”. International Society of Heart and Lung Transplant Conference, Orlando, April 2019